Abstracts for oral and/or poster presentation
Logistics
Abstracts may be submitted from 29 July 2024 to 15 January 2025
Abstracts must be written in English and relate to newborn screening and to the topics shown in the list below. Badly written abstracts and those unrelated to newborn screening will not be accepted.
Abstracts are uploaded to the https://membership.isns-neoscreening.org/abstract-submission
You are able to choose whether you would like to present the poster content as an oral or a poster
When you have uploaded your abstract, maximum 1800 characters excluding title and authors, you will be emailed a unique token number to permit editing your abstract later if wished
You will not be able to amend your abstract after 15 January 2025
The ISNS-ERM Local Organising Committee will review all abstracts and select those suitable for oral presentation
Three poster prizes will be available, kindly donated by the International Journal of Neonatal Screening. They will be awarded at the end of the conference to the posters with the best content and design as judged by 2 independent ISNS members.
All selected abstracts will be published in the International Journal of Neonatal Screening.
Directions for Posters:
Poster boards will be available with the following dimensions: 100 cm (wide) x 250 cm (tall).
The poster boards will fit a poster of A0 size. The poster board will be numbered in space above the poster at the top.
It is advised to bring your own adhesive tape (not pins!) to attach your poster(s).
For the benefit of interested visitors please bring 20-40 copies of your poster on A4 format.
Abstract topic list
Main topics for this conference (to be confirmed)
Long term outcome and governance of newborn screening cases detected, registries
Genetic testing in newborn screening
Ethical, legal and social implications of newborn screening including information provision, consent, opt in, opt out, GDPR and Psychosocial communication
Updates on screening for and new treatments for cystic fibrosis
Updates on neuromuscular disorders such as SMA
Newborn screening report from European countries
New technologies in screening:
Genomics
Proteomics
Metabolomics
Reactomics
Policy making and implementation:
Ethical, Legal and Social Implications, ELSI, of NBS
Providing information to the public
Providing information to professionals
Implementation of screening programmes in practice
Country progress reports
Conditions (to be ) screened for biochemically
Aminoacidaemias
Organic acidurias
Fatty Acid Oxidation disorders
Endocrine disorders (CH, CAH)
Cystic Fibrosis
Haemoglobinopathies
SCID
LSDs
SMA (Spinal Muscular Atrophy)
Duchenne muscular dystrophy
Fragile X
Bedside testing:
CCHD
Hearing
Process evaluation and improvement
Timeliness (sampling, sending, reporting)
Short term follow up
Long term follow up
Annual process evaluation protocols
Annual effect evaluation protocols
Automation
Collection paper technology and other microsampling techniques
Low-tech methodology in general
Contingency planning (fire, cyber attack, shortage of reagents)